Christian Marth

Christian Marth

UNVERIFIED PROFILE

Are you Christian Marth?   Register this Author

Register author
Christian Marth

Christian Marth

Publications by authors named "Christian Marth"

Are you Christian Marth?   Register this Author

100Publications

2349Reads

11Profile Views

Recurrence of genitals warts in pre-HPV vaccine era after laser treatment.

Arch Gynecol Obstet 2019 Sep 8;300(3):661-668. Epub 2019 Jul 8.

Department of Obstetrics and Gynecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-019-05242-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694085PMC
September 2019

Joint ENGOT and GOG Foundation requirements for trials with industry partners.

Int J Gynecol Cancer 2019 Sep 18;29(7):1094-1097. Epub 2019 Jul 18.

GOG-F and Gynecologic Oncology, Ohio State University Wexner Medical Center and JamesCare Gynecologic Oncology at Mill Run, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2019-000441DOI Listing
September 2019

Ovarian Cancer Stem Cell Heterogeneity.

Adv Exp Med Biol 2019 ;1139:201-221

Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-030-14366-4_12
Publisher Site
http://dx.doi.org/10.1007/978-3-030-14366-4_12DOI Listing
August 2019

Joint ENGOT and GOG Foundation requirements for trials with industry partners.

Gynecol Oncol 2019 08;154(2):255-258

GOG-F and Gynecologic Oncology, Ohio State University Wexner Medical Center and JamesCare Gynecologic Oncology at Mill Run, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.04.677DOI Listing
August 2019

Hopes and failures in front-line ovarian cancer therapy.

Crit Rev Oncol Hematol 2019 Aug 14;143:14-19. Epub 2019 Aug 14.

Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2019.08.002DOI Listing
August 2019

Clinical Impact of RANK Signalling in Ovarian Cancer.

Cancers (Basel) 2019 Jun 8;11(6). Epub 2019 Jun 8.

Department of Obstetrics and Gynaecology, Medical University of Innsbruck, 6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11060791DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627676PMC
June 2019

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.

N Engl J Med 2019 02;380(9):822-832

From the Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen (P. Harter, A. du Bois), Department of Gynecology, Charité-Universitätsmedizin Berlin, Berlin (J.S.), the Coordinating Center for Clinical Trials, Philipps University Marburg (A.R., C.S.-B.), and the Department of Gynecology and Obstetrics, University Hospital Giessen and Marburg (U.W.), Marburg, the Department of Gynecology and Obstetrics, Kaiserswerther Diakonie (B.L.), and the Department of Obstetrics and Gynecology, Heinrich-Heine-University Düsseldorf (W.M.), Düsseldorf, the Department of Gynecology and Obstetrics, University Medicine Greifswald, Greifswald (A.M.), the Department of Gynecology, University Medical Center Hamburg-Eppendorf (S.M.), and the Department of Gynecology and Obstetrics, Albertinen Krankenhaus (I.L.), Hamburg, University Women's Hospital, Department of Gynecology and Reproductive Medicine and Center for Gynecologic Oncology, Jena University Hospital, Jena (I.B.R.), the Department of Obstetrics and Gynecology, University Munich rechts der Isar (B.S.), and the Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-Universität München (A. Burges), Munich, West German Cancer Center, Department of Gynecology and Obstetrics, University of Duisburg-Essen, Duisburg (R.K.), the Department of Gynecology and Obstetrics, University Hospital Kiel, Kiel (F.H.), University Medical Center Freiburg, Freiburg (A.H.), University Medical Center Mainz, Department of Gynecology and Obstetrics, Mainz (A.H.), and the Department of Gynecology and Obstetrics, Hannover Medical School, Hannover (P. Hillemanns) - all in Germany; the Gynecologic Oncology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori (D.L., F.R.), and the Department of Gynecologic Oncology, European Institute of Oncology, University of Milan (G.A.), Milan, the Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome (G.S.), Gynecologic Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli, IRCCS Fondazione G. Pascale, Naples (S.G.), and the Cancer Reference Center, Centro di Riferimento Oncologico, Aviano (G.G.) - all in Italy; the Department of Gynecological Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium (I.V.); the Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria (C.M.); the Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea (J.-W.K.); and the Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (D.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1808424DOI Listing
February 2019

NADPH oxidase 4 expression in the normal endometrium and in endometrial cancer.

Tumour Biol 2019 Feb;41(2):1010428319830002

1 Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1010428319830002DOI Listing
February 2019

Immunotherapy in ovarian cancer: fake news or the real deal?

Int J Gynecol Cancer 2019 01;29(1):201-211

Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://ijgc.bmj.com/lookup/doi/10.1136/ijgc-2018-000011
Publisher Site
http://dx.doi.org/10.1136/ijgc-2018-000011DOI Listing
January 2019

Evaluation of Vav3.1 as prognostic marker in endometrial cancer.

J Cancer Res Clin Oncol 2018 Oct 6;144(10):2067-2076. Epub 2018 Aug 6.

Oncotyrol, Center for Personalized Cancer Medicine GmbH, 6020, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-018-2725-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153599PMC
October 2018

Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.

Authors:
Christian Marth

Expert Rev Anticancer Ther 2018 10;18(sup1):19-22

a Department of Obstetrics and Gynecology , Medical University of Innsbruck , Innsbruck , Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2018.1513793DOI Listing
October 2018

BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.

Br J Cancer 2018 09 15;119(6):683-692. Epub 2018 Aug 15.

Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0217-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173779PMC
September 2018

Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response.

Int J Cancer 2018 04 14;142(8):1640-1651. Epub 2017 Dec 14.

Department of Obstetrics and Gynecology, Medical University Innsbruck, 6020, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.31186
Publisher Site
http://dx.doi.org/10.1002/ijc.31186DOI Listing
April 2018

and mutation status associates with and expression in ovarian cancer.

Oncotarget 2018 Apr 3;9(25):17501-17511. Epub 2018 Apr 3.

Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck 6020, Austria.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/24770
Publisher Site
http://dx.doi.org/10.18632/oncotarget.24770DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915132PMC
April 2018

Managing relapsed ovarian cancer in a rapidly evolving landscape.

Future Oncol 2017 Oct 11;13(23s). Epub 2017 Oct 11.

Department of Obstetrics & Gynecology, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2017-0315
Publisher Site
http://dx.doi.org/10.2217/fon-2017-0315DOI Listing
October 2017

Platinum or nonplatinum in recurrent ovarian cancer: that is the question.

Future Oncol 2017 Oct 11;13(23s):11-16. Epub 2017 Oct 11.

Department of Obstetrics & Gynecology, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0317DOI Listing
October 2017

Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1.

J Comp Eff Res 2017 Oct 19;6(7):563-574. Epub 2017 Sep 19.

Institute of Public Health, Medical Decision Making & Health Technology Assessment, Department of Public Health, Health Services Research & Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics & Technology, Hall in Tirol, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cer-2017-0015DOI Listing
October 2017

L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer.

Int J Gynecol Pathol 2017 Jul;36(4):356-363

Departments of Obstetrics & Gynecology (S.A.A., I.M.D., S.F., A.G.Z., C.M.) Pathology (S.S.), Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000338DOI Listing
July 2017

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

N Engl J Med 2016 12 7;375(22):2154-2164. Epub 2016 Oct 7.

From the Nordic Society of Gynecological Oncology and Rigshospitalet-Copenhagen University Hospital, Copenhagen (M.R.M.), Odense University Hospital (J.H.) and European Network for Gynacological Oncological Trial and Research Unit of General Practice, Institute of Public Health, University of Southern Denmark, Odense (R.D.C.) - all in Denmark; University of Arizona and Creighton University-Phoenix, Phoenix (B.J.M.), and Arizona Oncology Associates, Tuscon (B.J.M., J.B.) - all in Arizona; Princess Margaret Consortium, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (A.M.O.), British Columbia Cancer Agency, Vancouver (A.V.T.), and McGill University-McGill University Health Centre, Montreal (L.G.) - all in Canada; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and the University of Munich, Munich (S.M.), and Kliniken Essen Mitte, Essen (A.B.) - both in Germany; Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Hospital Universitario La Paz (A.R.), and GEICO and M.D. Anderson Cancer Center Madrid (A.G.-M.), Madrid; French Investigator Group for Ovarian and Breast Cancer (GINECO) and Institut du Cancer de Montpellier, Montpellier (M.F.), and GINECO and Centre Antoine Lacassagne, Nice (P.F.) - both in France; National Cancer Research Institute and UCL Cancer Institute, University College London, London (J.A.L.); Multicenter Italian Trials in Ovarian Cancer/Mario Negri Gynecologic Oncology Group, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan (D.L.); Belgium and Luxembourg Gynecological Oncology Group and University of Leuven, Leuven, Belgium (I.V.); Kaplan Medical Center, Rehovot, Israel (N.E.B.-B.); AGO-Austria and Medical University Innsbruck, Innsbruck, Austria (C.M.); Central and Eastern European Gynecologic Oncology Group and Uniwersytet Medyczny w Poznaniu, Poznan, Poland (R.M.); Stanford Comprehensive Cancer Institute, Stanford (J.S.B.), and Cedars-Sinai Medical Center, West Hollywood (B.J.R.) - both in California; Oslo University Hospital, Radiumhospitalet, Oslo (A.D.); Northside Hospital, Atlanta (B.B.); Universitetssjukhuset, Linköping, Sweden (P.R.); and Veristat, Southborough (J.P.B.), Tesaro, Waltham (S.A.), and Dana-Farber Cancer Institute, Boston (U.A.M.) - all in Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611310DOI Listing
December 2016

Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.

Expert Rev Anticancer Ther 2016 Nov;16(sup1):11-19

e Clinical Area of Gynecological Cancer , Fundación Instituto Valenciano de Oncología , Valencia , Spain.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737140.2016.1
Publisher Site
http://dx.doi.org/10.1080/14737140.2016.1243475DOI Listing
November 2016

European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery.

Int J Gynecol Cancer 2016 09;26(7):1354-63

*Institut Bergonié, Bordeaux, France; †MD Anderson Cancer Center, Madrid, Spain; ‡Imperial College London; §Royal Marsden Hospital, London, United Kingdom; ∥Charles University Hospital, Prague, Czech Republic; ¶European Institute of Oncology, Milan, Italy; #Leiden University Medical Center, Leiden, the Netherlands; **Norwegian Radium Hospital, Oslo, Norway; ††Kliniken Essen-Mitte, Essen, Germany; ‡‡Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; §§Innsbrück Medical University, Innsbruck, Austria; ∥∥Institut Gustave Roussy, Villejuif, France; ¶¶Weill Cornell Medical College, Doha, Qatar; ##Centre Leon Berard, Lyon, France; ***Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; †††University Medical Center, Groningen, the Netherlands; and ‡‡‡University Hospital Leuven, Catholic University Leuven, Leuven, European Union, Belgium.

View Article

Download full-text PDF

Source
https://www.esgo.org/wp-content/uploads/2016/10/Journal-arti
Web Search
http://dx.doi.org/10.1097/IGC.0000000000000767DOI Listing
September 2016

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).

J Clin Oncol 2016 07 6;34(21):2516-25. Epub 2016 Jun 6.

Christian Kurzeder and Andreas du Bois, Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Kliniken Essen Mitte, Essen; Frederik Marmé, AGO and University Hospital Heidelberg, Heidelberg; Joern Rau and Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg; Sven Mahner, AGO and University Medical Center Hamburg-Eppendorf, Hamburg; Sandra Polleis, AGO Study Group, Wiesbaden, Germany; Isabel Bover, Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Hospital Son Llàtzer, Palma de Mallorca; Pilar Barretina-Ginesta, GEICO and Catalan Institute of Oncology, Girona; Josep M. del Campo, GEICO and Vall d'Hebron University Hospital, Barcelona; Antonio Gonzalez-Martin, GEICO and MD Anderson Cancer Center Spain, Madrid, Spain; Patricia Pautier, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Institut Gustave Roussy, Villejuif; Anne Floquet, GINECO and Institut Bergonié, Bordeaux, France; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan Bicocca-European Institute of Oncology; Domenica Lorusso, Multicenter Italian Trials in Ovarian Cancer and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, National Cancer Institute, Milan, Italy; Petronella Ottevanger, Dutch Gynecological Oncology Group and Radboud University Medical Center, Nijmegen, the Netherlands; Maria Bjurberg, Nordic Society of Gynecological Oncology and Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden; Christian Marth, AGO-Austria and Innsbruck Medical University, Innsbruck, Austria; Ignace Vergote, AGO and University Hospital Leuven, Leuven, Belgium; and Lydie Bastière-Truchot, Nicolas Martin, Mikkel Z. Oestergaard, and Astrid Kiermaier, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.0787DOI Listing
July 2016

The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

Tumour Biol 2016 Mar 29;37(3):3009-16. Epub 2015 Sep 29.

Department of Gynecology, Tumor Bank Ovarian Cancer (TOC), European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13277-015-4031-9DOI Listing
March 2016

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.

Int J Gynecol Cancer 2016 Jan;26(1):2-30

*Division of Medical Gynecologic Oncology, European Institute of Oncology and University of Milan-Bicocca, Milan, Italy; †Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands; ‡Department of Gynecological Oncology, University Hospital Leuven, Leuven, Belgium and Center for Gynecological Oncology Amsterdam (CGOA), Antoni van Leeuwenhoek, Amsterdam, The Netherlands; §Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; ∥Medical Oncology Department, GEICO and MD Anderson Cancer Center, Madrid, Spain; ¶Department of Oncology and Cancer Trials, UCL Cancer Institute, London, United Kingdom; #Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria; **Department of Radiotherapy, Leiden University Medical Center, Leiden, The Netherlands; ††Department of Surgery, Institut Bergonié, Bordeaux, France and Gynecology and Obstetrics Department, McGill University Health Centre, Montreal, Quebec, Canada; ‡‡Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; and §§Department of Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://www.esgo.org/wp-content/uploads/2015/12/ESMO_ESGO_EST
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/IGC.0000000000000609DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679344PMC
January 2016

Dual-energy contrast-enhanced spectral mammography (CESM).

Arch Gynecol Obstet 2015 Oct 27;292(4):739-47. Epub 2015 Mar 27.

Department of Radiology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-015-3693-2DOI Listing
October 2015

AGO Austria recommendations for genetic testing of patients with ovarian cancer.

Wien Klin Wochenschr 2015 Aug;127(15-16):652-4

Clinic for Gynecology and Obstetrics, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00508-015-0814-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536270PMC
August 2015

Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.

Cancer Metastasis Rev 2015 Mar;34(1):41-52

Department of Obstetrics and Gynaecolog, Leuven Cancer Institute, University Hospital Leuven, Herestraat 49, 3000, Leuven, Belgium,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-014-9539-8DOI Listing
March 2015

Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.

Int J Gynecol Cancer 2015 Feb;25(2):257-62

*Department of Obstetrics and Gynecology, and †Study Center of AGO (Arbeitsgemeinschaft für Gynäkologisch Onkologie) Austria, Innsbruck Medical University, Innsbruck; ‡Department of Gynecology and Gynecologic Oncology, Medical University of Vienna, Vienna; §Department of Obstetrics and Gynecology, Medical University of Graz; ∥Department of Gynecology, Krankenhaus der Barmherzigen Brüder Graz, Graz; ¶Department of Obstetrics and Gynecology, Krankenhaus Oberpullendorf, Oberpullendorf; #Department of Obstetrics and Gynecology, Wilhelminenspital Wien, Vienna; **Department of Obstetrics and Gynecology, KH der Kreuzschwestern Wels, Wels; and ††Department of Obstetrics and Gynecology, KH Ried i.I. Schloßberg 1, Ried im Innkreis, Austria.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/IGC.0000000000000352DOI Listing
February 2015

Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.

BMC Cancer 2015 Feb 6;15:33. Epub 2015 Feb 6.

Queensland Centre for Gynaecological Oncology, University of Queensland, School of Medicine, Central Clinical Division, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://bmccancer.biomedcentral.com/articles/10.1186/s12885-0
Publisher Site
http://dx.doi.org/10.1186/s12885-015-1028-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342867PMC
February 2015

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

J Clin Oncol 2014 Oct 15;32(30):3374-82. Epub 2014 Sep 15.

Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.7348DOI Listing
October 2014

Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients.

Eur J Cancer 2014 Aug 5;50(12):2134-41. Epub 2014 Jun 5.

Vorarlberg Institute for Vascular Investigation and Treatment, 6800 Feldkirch, Austria; Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, 6800 Feldkirch, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.05.007DOI Listing
August 2014

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.

J Clin Oncol 2014 Feb 23;32(4):320-6. Epub 2013 Dec 23.

Ignace B. Vergote and Evelyn Despierre, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven; Corneel Coens, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Antonio Jimeno, University of Colorado School of Medicine, Aurora, CO; Florence Joly, Centre François Baclesse Caen, Caen; Anne Lesoin, Centre Oscar Lambret, Lille; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Laure Favier, Centre Georges François Leclerc, Dijon; Hervé Curé, Unicancer Institut Jean Godinot, Reims; Eric Pujade-Lauraine, Hôpital Hôtel-Dieu, Paris, France; Dionyssios Katsaros, University of Turin; Annamaria Ferrero, Ospedale Mauriziano Umberto I, Turin; Nicoletta Colombo, University of Milan-Bicocca and Istituto Europeo di Oncologia, Milan, Italy; Christian Marth, Medical University of Innsbruck, Innsbruck; Alexander Reinthaller, Medical University of Vienna, Vienna, Austria; Marcia Hall, Mount Vernon Cancer Centre, Middlesex; John Green, University of Liverpool, Liverpool; Nick Simon Reed, Gartnavel General Hospitals, Glasgow, United Kingdom; Christopher B. Steer, Border Medical Oncology, Wodonga; Martin Buck, Government of Western Australia, Department of Health, Perth, Australia; and Antonio Casado, Universitario San Carlos, Madrid, Spain.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2013/12/23/JCO.2013.50
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.50.5669
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.50.5669DOI Listing
February 2014

Interactions of human peritoneal mesothelial cells with serous ovarian cancer cell spheroids--evidence for a mechanical and paracrine barrier function of the peritoneal mesothelium.

Int J Gynecol Cancer 2014 Feb;24(2):192-200

*Institute of Pathology, Kantonsspital Baden AG, Baden, Switzerland; Departments of †Pathology, ‡Gynecology and Obstetrics, and §Internal Medicine, Innsbruck Medical University, Innsbruck, Austria; ∥Department of Clinical Chemistry, Robert Bosch Hospital, Stuttgart, Germany; and ¶Institute of Pathology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000036DOI Listing
February 2014

Endometroid carcinoma developing in endometriosis over the symphysis pubis.

Gynecol Oncol Case Rep 2013 10;6:45-6. Epub 2013 Sep 10.

Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S2211338X130006
Publisher Site
http://dx.doi.org/10.1016/j.gynor.2013.08.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862317PMC
December 2013

Conservative management of abnormally invasive placenta: four case reports.

Acta Obstet Gynecol Scand 2013 Apr 14;92(4):468-71. Epub 2013 Feb 14.

Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aogs.12079DOI Listing
April 2013

Migrants and obstetrics in Austria--applying a new questionnaire shows differences in obstetric care and outcome.

Wien Klin Wochenschr 2013 Jan 5;125(1-2):34-40. Epub 2013 Jan 5.

Department of Clinical Epidemiology, Tyrolean State Hospitals Ltd., Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00508-012-0312-0DOI Listing
January 2013

HE4 is an independent prognostic marker in endometrial cancer patients.

Gynecol Oncol 2012 Aug 21;126(2):186-91. Epub 2012 Apr 21.

Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2012.04.022DOI Listing
August 2012

Role of pertuzumab in the treatment of HER2-positive breast cancer.

Breast Cancer (Dove Med Press) 2012 May 28;4:65-73. Epub 2012 May 28.

Brustgesundheitzentrum Tirol, Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BCTT.S23560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846374PMC
May 2012

International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG).

Int J Radiat Oncol Biol Phys 2012 Jan 22;82(1):250-5. Epub 2010 Dec 22.

Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2010.10.030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489266PMC
January 2012

Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients.

Breast Cancer Res Treat 2011 Nov 8;130(1):109-17. Epub 2011 Jan 8.

Department of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-010-1335-8DOI Listing
November 2011

Evidence for cosmetics as a source of mineral oil contamination in women.

J Womens Health (Larchmt) 2011 Nov 4;20(11):1713-9. Epub 2011 Oct 4.

Department of Obstetrics and Gynecology, Innsbruck Medical University, Anichstrasse 35, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jwh.2011.2829DOI Listing
November 2011

Is neoadjuvant chemotherapy in ovarian cancer an excuse for insufficient surgery?

Oncology (Williston Park) 2011 Sep;25(10):940, 942, 944

Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
September 2011

Fatal invasive cervical cancer secondary to untreated cervical dysplasia: a case report.

J Med Case Rep 2011 Jul 18;5:316. Epub 2011 Jul 18.

Department of Obstetrics and Gynecology, Innsbruck Medical University, Anichstrasse 35, AT-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1752-1947-5-316DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156764PMC
July 2011

DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer.

Gynecol Oncol 2011 Apr 20;121(1):24-31. Epub 2011 Jan 20.

Department of Gynecology and Obstetrics, Informatics and Health Economics, Innsbruck Medical University, Innsbruck, Austria, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2010.12.332DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062717PMC
April 2011

Introduction of organised mammography screening in Tyrol: results of a one-year pilot phase.

BMC Public Health 2011 Feb 9;11:91. Epub 2011 Feb 9.

Department of Clinical Epidemiology of the Tyrolean State Hospitals Ltd, Cancer Registry of Tyrol, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://bmcpublichealth.biomedcentral.com/articles/10.1186/14
Publisher Site
http://dx.doi.org/10.1186/1471-2458-11-91DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048536PMC
February 2011

Use of IP chemotherapy in ovarian cancer: the critical questions.

Oncology (Williston Park) 2011 Feb;25(2):170, 173-4

National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
February 2011

Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer.

Cancer Immunol Immunother 2010 Dec 18;59(12):1813-23. Epub 2010 Aug 18.

Department of Obstetrics and Gynecology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-010-0907-0DOI Listing
December 2010

Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.

Wien Med Wochenschr 2010 Nov 26;160(19-20):506-12. Epub 2010 Oct 26.

Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10354-010-0838-6
Publisher Site
http://dx.doi.org/10.1007/s10354-010-0838-6DOI Listing
November 2010

High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer.

Gynecol Oncol 2010 Sep 17;118(3):244-50. Epub 2010 Jun 17.

Tyrolean Cancer Research Institute Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2010.05.024DOI Listing
September 2010

Importance of erythropoetin receptor expression in tumour tissue for the clinical course of breast cancer.

Anticancer Res 2010 Sep;30(9):3721-6

Department of Obstetrics and Gynecology, Clinical Immunology and Infectious Diseases, Innsbruck Medical University, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
September 2010

E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer.

Cancer Res 2010 Jun 11;70(11):4613-23. Epub 2010 May 11.

Departments of Obstetrics and Gynecology and Radiotherapy, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-09-3551DOI Listing
June 2010

Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.

Wien Med Wochenschr 2010 Apr;160(7-8):167-73

Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10354-010-0771-8
Publisher Site
http://dx.doi.org/10.1007/s10354-010-0771-8DOI Listing
April 2010